HER2+ve Breast Cancer by Bhawna Sirohi
Session 3 : HER2+ve Breast Cancer
Chairpersons :
A K Malhotra, S H Advan
Speaker :
Bhawna Sirohi
Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer
Author: Grazia Arpino
Conference: 2016 SABCS S3-04
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab
Author: Hannah Dzimitrowicz
Reference: Journal of Clinical Oncology 34, no. 29 (October 2016) 3511-3517
PHEREXA: A phase III study of trastuzumab + capecitabine +/- pertuzumab for patients who progressed during/after one line of trastuzumab-based therapy in the HER2 positive metastatic breast cancer setting
Author: Urruticoechea A
Conference: 2016 ASCO Annual Meeting, LBA 503